Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Coherus Oncology, Inc.

Contributing Author

Recent Articles by Coherus Oncology, Inc.

Nov-09
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan CHRS +6.18% GlobeNewswire
Oct-28
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development CHRS +8.41% CHRS -22.55% GlobeNewswire
Oct-27
Coherus to Participate in Upcoming Investor Conferences CHRS +5.94% GlobeNewswire
Oct-26
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 CHRS GlobeNewswire
Oct-14
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 CHRS GlobeNewswire
Sep-23
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets CHRS GlobeNewswire
Aug-31
Coherus to Participate in Upcoming Investor Conferences CHRS GlobeNewswire
Aug-17
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights CHRS CHRS +16.52% GlobeNewswire
Aug-05
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update CHRS CHRS -12.76% GlobeNewswire
Jul-22
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 CHRS GlobeNewswire
Jun-23
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) CHRS GlobeNewswire
May-11
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update CHRS +11.43% CHRS -12.31% GlobeNewswire
May-04
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 CHRS GlobeNewswire
Mar-09
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update CHRS +6.04% GlobeNewswire
Mar-02
Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 CHRS GlobeNewswire
Feb-23
Coherus Oncology to Participate in Upcoming Investor Conferences CHRS GlobeNewswire
Feb-17
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock CHRS GlobeNewswire
Feb-12
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock CHRS -19.90% GlobeNewswire
Feb-12
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock CHRS CHRS -19.90% GlobeNewswire
Jan-06
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference CHRS -5.56% GlobeNewswire
Jan-05
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) CHRS +5.11% GlobeNewswire
Dec-08
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma CHRS +6.67% GlobeNewswire
Nov-07
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody CHRS -10.07% GlobeNewswire
Nov-06
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update CHRS GlobeNewswire
Nov-06
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer CHRS CHRS -10.07% GlobeNewswire
Oct-30
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 CHRS GlobeNewswire
Oct-23
Coherus Oncology to Participate in Upcoming Investor Conferences CHRS GlobeNewswire
Oct-03
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) CHRS GlobeNewswire
Sep-03
Coherus Oncology to Participate in Upcoming Investor Conferences CHRS +5.88% GlobeNewswire
Aug-07
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update CHRS CHRS -7.13% GlobeNewswire
Jul-31
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 CHRS CHRS -6.64% GlobeNewswire
May-30
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics CHRS GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)